Daniel Guerrero-Romero

Cancer Research UK Cambridge Center — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

3h-index19citations17works0.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(12), Bioinformatics and Genomic Networks(11), Computational Drug Discovery Methods(9), Cancer Cells and Metastasis(2), Single-cell and spatial transcriptomics(2)

Publications17 total

Real-time cell viability monitoring for high-throughput drug screening using tumour xenograft-derived cells
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
Real-time cell viability monitoring for high-throughput drug screening using tumour xenograft-derived cells
Zenodo (CERN European Organization for Nuclear Research)·2026Open Access
The tumor microenvironment of 14,837 breast cancers is associated with clinical outcome independently of genomic subtypes
Cell Reports Medicine·2025Open Access
Fitness and transcriptional plasticity of human breast cancer single-cell-derived clones
Cell Reports·2025· 3 citedOpen Access
Figure 4 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
2025Open Access
Figure 6 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
2025Open Access
Figure 5 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
2025Open Access
Figure 3 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
2025Open Access
Data from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
2025· 1 citedOpen Access
Supplementary Legends from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
2025Open Access
Supplementary Tables 1-5 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
2025Open Access
Supplementary Figures 1-20 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
2025Open Access
Figure 1 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
2025Open Access
Figure 2 from Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
2025Open Access
Modeling Drug Responses and Evolutionary Dynamics Using Patient-Derived Xenografts Reveals Precision Medicine Strategies for Triple-Negative Breast Cancer
Cancer Research·2024· 3 citedOpen Access
Modelling drug responses and evolutionary dynamics using triple negative breast cancer patient-derived xenografts
2023Open Access
The Cholinergic System Contributes to the Immunopathological Progression of Experimental Pulmonary Tuberculosis
Frontiers in Immunology·2021· 12 citedOpen Access

Frequent Co-authors

Elham Esmaeilishirazifard(15), Raquel Manzano García(14), Oscar M. Rueda(14), Carlos Caldas(14), Giulia Lerda(13), Helen Bardwell(13), Wendy Greenwood(13), Alejandra Bruna(13), Riccardo Masina(12), Abigail Shea(12), Dimitra Georgopoulou(12), Maurizio Callari(12), Sophia Wix(12), Agnese Giovannetti(12), Alistair Martin(12), A. Nagano(12), Lisa Young(12), Steven Kupczak(12), Elena Provenzano(12), Jonny Lay(12)